Business1 min read

Multibagger Cupid to be in focus on Thursday after Q2 net profit more than doubles to ₹56 crore; raises FY27 guidance

By · Published by Everything Blog

In short

The manufacturer's earnings momentum was led by its domestic consumer healthcare segment, which represented 67% of total sales during the first half of FY27 at ₹224.64 crore. Global demand was reinforced by overseas price revisions, an agreement with PFSCM, and ongoing supplies for South Africa's national programme. Bolstered by these revenue channels and an expanding retail network, leadership significantly upgraded its multi-year operational targets through FY29.

Key points

  • Full-year FY27 guidance was raised to at least ₹880 crore in revenue and ₹275 crore or mo…: Full-year FY27 guidance was raised to at least ₹880 crore in revenue and ₹275 crore or more in net profit.
  • First-half net profit advanced 156% to reach ₹100.37 crore on total operational revenue o…: First-half net profit advanced 156% to reach ₹100.37 crore on total operational revenue of ₹342.58 crore.
  • Medium-term projections now forecast FY29 revenue to exceed ₹1,950 crore with net profit…: Medium-term projections now forecast FY29 revenue to exceed ₹1,950 crore with net profit near ₹605 crore.

Sources checked by our analysis pipeline: 1

Multibagger Cupid shares are likely to be on investors' radar on Thursday, 12 November, as the company posted another solid quarter, led by consumer healthcare and FMCG business.

The company posted a 133% year-on-year jump in Q2 FY27 net profit to ₹56.22 crore, compared with ₹24.13 crore in the year-ago period. For the first half of FY27, net profit surged 156% YoY to ₹100.37 crore from ₹39.14 crore in H1 FY26.

Revenue from operations grew 122% YoY to ₹187.86 crore in Q2 FY27 and 137% to ₹342.58 crore in H1 FY27. EBITDA for H1 FY27 stood at ₹114.83 crore, registering 156% growth year-on-year, while Q2 EBITDA came in at ₹54.77 crore, with a margin of 29%.

Cupid's strong performance was supported by growing contributions from its domestic consumer healthcare and FMCG business, alongside sustained demand in its international healthcare operations.

The domestic business contributed ₹224.64 crore, accounting for 67% of H1 FY27 sales, compared with 41% in FY26. The Consumer Healthcare & FMCG segment alone contributed ₹166.88 crore, representing 49% of sales, highlighting the increasing scale of its consumer portfolio.

Business